Based on the observed overexpression of EZH2 in many cancer types and the correlation with poor patient outcome, the pathological function of EZH2 has generally been attributed to hyperactivation of the PRC2 methyltransferase activity and strengthened repression at existing target genes (e.g. CDKN2A/p16) 65. This evidence concerns the gene EZH2 and cancer.